Related Experiment Video
Updated: Sep 28, 2026
Captive Maintenance and Venom Extraction of Tityus serrulatus (Brazilian Yellow Scorpion) for Antivenom Production
Published on: October 6, 2023
[Clinical and biological surveillance of envenomed patients]
1Service d'anesthésie-réanimation, Hôpital d'instruction des armées Bégin, Saint-Mandé, France.
Abstract:
Faced with an envenomation, the problem is to take sufficiently rapidly the decision to administer the only effective treatment--immunotherapy--, to know which antivenom to choose and how long to administrate it. If the snake is not identified, symptoms and initial development give information on the type of venom. It is convenient to classify the symptoms according to four clinical types: i) the cobra syndrome with a potentially fatal evolution within two to ten hours and which resembles an Elapid bite, ii) the viper syndrome associating bleeding and inflammation, which can be due either to a viper, pit viper or, in Australia, to Elapids, iii) disturbance of blood circulating functions and iv) disturbance of other live functions. Between the third to the half of snakebite victims present no envenomation. Severe envenomations must be monitored in an intensive care unit, with experience in emergency management and monitoring of patients with major life-threatening conditions. Throughout the world, snakebites induce more than 100,000 deaths every year. Schematically, the emergency may be considered in terms of seconds for blood circulation disorders, minutes for respiratory paralysis, and hours for the coagulopathy.
Insights
Rapidly identifying snakebite symptoms is crucial for effective immunotherapy. Prompt clinical assessment guides antivenom selection and administration, improving outcomes for envenomation victims.
Area of Science:
- Toxicology
- Clinical Medicine
- Emergency Medicine
Context:
- Snakebite envenomation presents a significant global health challenge, causing over 100,000 deaths annually.
- Accurate and timely diagnosis is critical for effective treatment, yet snake identification is often challenging.
- Clinical presentation and symptom progression provide vital clues for determining the type of venom and appropriate management.
Purpose:
- To outline a clinical approach for managing snakebite envenomations when the snake species is unknown.
- To categorize common snakebite syndromes and their associated clinical timelines.
- To emphasize the importance of rapid decision-making for immunotherapy and antivenom administration.
Summary:
- Envenomation management requires swift decisions regarding immunotherapy, antivenom choice, and duration of treatment.
- Clinical syndromes are classified into four types: cobra syndrome (Elapid-like), viper syndrome (bleeding/inflammation), and disturbances of circulatory or other vital functions.
- Approximately 33-50% of snakebite victims do not experience envenomation; severe cases necessitate intensive care unit monitoring.
Impact:
- Improved emergency response protocols for snakebite victims.
- Enhanced clinical decision-making in resource-limited settings.
- Potential reduction in snakebite-related morbidity and mortality worldwide.
Related Concept Videos
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:23Investigation of Disease Outbreaks